Select therapeutic use:
Indications for CEREZYME:
For long-term enzyme replacement therapy in patients with confirmed Type 1 Gaucher disease that results in one or more of the following conditions: 1) anemia; 2) thrombocytopenia; 3) bone disease; 4) hepatomegaly or splenomegaly.
Adults and Children:
<2yrs: not recommended. ≥2yrs: Give by IV infusion over 1–2 hours. Individualize. Initial dose range: 2.5 Units/kg 3 times a week to 60 Units/kg once every 2 weeks.
Monitor periodically for IgG antibody formation during the first year. Patients previously treated with Ceredase (alglucerase inj) who have developed antibody or hypersensitivity to Ceredase. Monitor for pulmonary hypertension, pneumonia. Pregnancy (Cat.C). Nursing mothers.
GI upset, abdominal pain, rash, pruritus, fatigue, headache, fever, dizziness, chills, backache, tachycardia, inj site reactions, hypersensitivity. Also children: dyspnea, flushing, coughing,